Study on the potential of RGD- and PHSRN-modified alginates as artificial extracellular matrices for engineering bone

Ryusuke Nakaoka1, Yoshiaki Hirano, David J Mooney

  • 1Division of Medical Devices, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan, nakaoka@nihs.go.jp.

Summary

Modifying alginate gels with specific peptide sequences, arginine-glycine-aspartic acid (RGD) and proline-histidine-serine-arginine-asparagine (PHSRN), significantly influences normal human osteoblast behavior and differentiation for bone tissue engineering.

Related Concept Videos